Mycoplasma Testing Market Size & Share Analysis Report, 2032
Mycoplasma Testing Market Size, Global Analysis Report, 2024-2032

Mycoplasma Testing Market Share, Size, Trends, Industry Analysis Report, By Product & Service (Assays, Kits, & Reagents, Instruments, Services); By Technique; By Application; By End User; By Region; Segment Forecast, 2024 - 2032

  • Published Date:Jan-2024
  • Pages: 118
  • Format: PDF
  • Report ID: PM1785
  • Base Year: 2023
  • Historical Data: 2019 – 2022

Report Outlook

Mycoplasma Testing Market size was valued at USD 942.01 million in 2023. The market is anticipated to grow from USD 1064 million in 2024 to USD 2909 Mn by 2032, exhibiting the CAGR of 13.4% during the forecast period.

Market Overview

Mycoplasma is a typical microorganism that is known as a smaller living bacterium. This causes respiratory tract infections in human beings and animals. There are two types of mycoplasmas that can cause harm to humans: mycoplasma pneumoniae, which acts on the respiratory system, and mycoplasma genitalium, which is a sexually transmitted disease. Growing cell and gene therapies is likely to stimulate mycoplasma testing growth, as mycoplasma is expected to exist in 35% of cell cultures incorporated in research and cell therapies, making the detection of mycoplasma crucial among researchers.

  • For instance, in January 2023, a study published in the Journal of Clinical Microbiology conducted a comparative study of five commercial molecular assays pertaining to mycoplasma testing of cellular therapy products.

Moreover, the ability of mycoplasma to modify cell physiology in cell cultures is emphasizing researchers to focus on diagnostic tests to detect mycoplasma, as it can alter the results of experiments.

However, the lower availability of suitable infrastructure for mycoplasma testing and continuous improvement in the testing methods are likely to hamper the growth of the global market.

Mycoplasma Testing Market Size

To Understand More About this Research: Request a Free Sample Report

Growth Drivers

  • Rising research studies exploring mycoplasma detection

The rising awareness about the side effects associated with the medicines or therapeutics with harmful microorganisms, including mycoplasma, is fostering the need to utilised diagnostic tests to evaluate the safety and quality in the marketplace. A 2023 study published in MDPI focused on exploring the development and evaluation of qPCR assays for detecting mycoplasma in cell cultures.

  • The growing incidence of mycoplasma-related health issues

The prevalence of health problems associated with the intake of mycoplasma-contaminated medicine, therapies, or food is positively influencing the adoption of mycoplasma testing in the food and healthcare industries. According to the National Health Commission, in November 2023, China registered a significant rise in hospital admissions and outpatient consultations due to Mycoplasma pneumoniae. This trend is expected to drive new potential opportunities for mycoplasma testing in the forecast timeframe.

 Mycoplasma Testing

Restraining Factors

  • The researchers' resistance in adopting new innovations.

The higher costs of deploying testing infrastructure, along with the need to adopt ongoing technological innovations, are expected to restrain mycoplasma testing market growth. Academicians and researchers are anticipated to show reluctance to embrace the latest innovations, embarking on a significant obstacle to the expansion of the mycoplasma testing market.

Report Segmentation

The market is primarily segmented based on product & service, technique, application, end user and region.

By Product & Service

By Technique

By Application

By End User

By Region

  • Assays, Kits, & Reagents
  • NAT assays, kits, & reagents
  • ELISA assays, kits, & reagents
  • Elimination Kits
  • Stains
  • Other assays, kits, & reagents
  • Instruments
  • Services


  • NAT
  • Staining
  • Other technique



  • Cell line testing
  • Virus Testing
  • End-of-Production cell testing



  • Pharmaceutical & Biotechnology Companies
  • Cell Banks & Laboratories
  • Contract Research Organizations
  • Academic Research Institutes
  • North America (U.S., Canada)
  • Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia)
  • Asia Pacific (Japan, China, India, Malaysia, Indonesia. South Korea)
  • Latin America (Brazil, Mexico, Argentina)
  • Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa)

To Understand the Scope of this Report: Speak to Analyst

By Products & Services Analysis

  • Assays, Kits, & Reagents segment poised to witness the highest growth during the forecast period

The assays, kits, and reagents segment is expected to grow at a reasonable CAGR during the anticipated period, fairly attributable to the rising new development of therapeutics, primarily cell and gene, contributing to the need for kits, reagents, and assays to test the presence of mycoplasma, as it can mislead to an inaccurate outcome of therapy. 

The instruments segment led the industry market with a substantial revenue share in 2023, largely attributable to the increasing demand for accurate, fast, and cost-effective testing solutions in the marketplace. The capability of testing instruments to detect harmful bacteria in medicines promotes the safety and efficacy of cell-based therapies.

By Technique Analysis

  • NAT segment witnessed the largest market share in 2023

The NAT (nucleic acid amplification) segment registered for the largest market share in 2023 and is expected to continue its market position throughout the study period. The numerous advantages of NAT, including robustness, sensitivity, and faster results, are contributing to the increased adoption of this technology in mycoplasma testing.

The ELISA (enzyme-linked immunosorbent assay) segment is expected to grow at the fastest rate over the next few years on account of the rapid increase in demand for cell banks. It is widely used in laboratory tests to identify antibodies in blood against mycoplasma pneumonia.

By Application Analysis

  • Cell line testing segment held the significant market revenue share in 2023

The cell line testing segment held a significant share in 2023, due to the continuous rise in the use of cell cultures. The growing research and development activities in the production and manufacturing of medicines necessitate the need to employ mycoplasma testing, driving substantial investments in cell line testing.

Based on the mycoplasma testing market analysis, the end-of-production cell testing segment is the second-growing segment by application. This is attributable to its ability to check the production system of medicine and assist in reducing contamination issues.

By End User Analysis

  • Pharmaceutical & biotechnology companies segment registered a dominant share in 2023

The Pharmaceutical & Biotechnology Companies segment witnessed a dominant share in the 2023 mycoplasma analysis and is anticipated to continue its trend throughout the study period. Pharmaceutical and biotechnology companies are showing enormous interest in the innovation of effective medicine with cell and gene therapies, facilitating the significant demand for mycoplasma testing in the market.

Contract research organizations segment is expected to register significant growth in the next few years, driven by the rising establishment of contract research organizations as they are specialised in offering services in the development, production, and testing of biopharmaceutical products, gaining traction among researchers.

 Mycoplasma Testing Seg

Regional Insights

  • North America region registered the largest share of the global market in 2023

The North America region dominated the global market. This dominance is due to high prevalence of respiratory disorders and substantial investments made by major companies in biotechnology. This increased investment is a response to the growing adoption of biotechnology in various areas, including cancer research, and the development of new biologics, vaccines, and drugs.

The Asia Pacific region is poised to be the fastest growing region with a higher CAGR during the forecast timeframe, owing to the presence of major players focusing on the production of reliable medicines and therapies. For instance, in May 2023, HiMedia Laboratories announced the new initiative to offer customized testing services for mycoplasma cell line detection, drug screening, cell line authentication, and bioproduction platforms. This trend is expected to create mycoplasma testing opportunities in the region.

 Mycoplasma Testing Reg

Key Market Players & Competitive Insights

  • Rising product innovations will drive advancements in the marketplace

The mycoplasma testing market is characterized by a mixture of consolidation and fragmentation, with the presence of several players and a few larger players. It is anticipated to witness significant competition with the research activities to innovate new testing techniques to determine mycoplasma early. For instance, in February 2023, SwiftDx unveiled a mycoplasma detection kit with the capability to offer a faster and more convenient solution.

Some of the major players operating in the global market include:

  • Agilent Technologies (US)
  • American Type Culture Collection (US)
  • Biological Industries Israel Beit Haemek Ltd. (Israel)
  • Bionique Testing Laboratories, Inc. (US)
  • Biotools B & M Labs, S.A. (Spain)
  • Charles River Laboratories International, Inc. (US)
  • Creative Bioarray (US)
  • Eurofins Scientific (Luxembourg)
  • GeneCopoeia, Inc. (US)
  • GenBio (Canada)
  • InvivoGen (US)
  • Lonza Group Ltd. (Switzerland)
  • Merck KGaA (Germany)
  • Meridian Bioscience, Inc. (US)
  • Minerva Biolabs GmbH (Germany)

Recent Developments in the Industry

  • In May 2023, a study published in Science Direct focused on the development of mycoplasma testing that can detect 90% of the presence of mycoplasma with the PCR standard protocol.

Report Coverage

The mycoplasma testing market report emphasizes on key regions across the globe to provide better understanding of the product to the users. Also, the report provides market insights into recent developments, trends and analyzes the technologies that are gaining traction around the globe. Furthermore, the report covers in-depth qualitative analysis pertaining to various paradigm shifts associated with the transformation of these solutions.

The report provides detailed analysis of the market while focusing on various key aspects such as competitive analysis, product & service, technique, application, end user and their futuristic growth opportunities.

Mycoplasma Testing Market Report Scope

Report Attributes


Market size value in 2024

USD 1064.00 million

Revenue forecast in 2032

USD 2909.64 million


13.4% from 2024 – 2032

Base year


Historical data

2019 – 2022

Forecast period

2024 – 2032

Quantitative units

Revenue in USD million and CAGR from 2024 to 2032

Segments covered

  • By Product & Service
  • By Technique
  • By Application
  • By End User
  • By Region

Regional scope

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Competitive Landscape

  • Mycoplasma Testing Market Share Analysis (2023)
  • Company Profiles/Industry participants profiling includes company overview, financial information, product/service benchmarking, and recent developments

Report Format

  • PDF + Excel


Report customization as per your requirements with respect to countries, region and segmentation.


The global mycoplasma testing market size is expected to reach USD 2909.64 Million by 2032

Key players in the market are Agilent Technologies, American Type Culture Collection, Biological Industries Israel Beit Haemek Ltd

North America contribute notably towards the global Mycoplasma Testing Market

Mycoplasma Testing Market exhibiting the CAGR of 13.4% during the forecast period.

The Mycoplasma Testing Market report covering key segments are product & service, technique, application, end user and region.